Evaluation the Growth Factors(IGF-1,IGFBP-3and HGH)in Patients With Chronic Liver Disease
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
BACKGROUND The insulin-like growth factor system (IGFs) plays an important role in cell growth and differentiation. Nevertheless, the roles played by insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3) and human growth hormone (HGH) in the progression of chronic liver disease remain to be elucidated and investigated.
METHODS The subjects in the present study included 60 healthy controls, 30 hepatitis patients, 60 liver cirrhosis patients and 60 untreated hepatocellular carcinoma patients. Blood was drawn by venipuncture into Venoject tubes. To find the possible correlations between liver damage and IGFs, serum IGF-1, GH, IGFBP-3 concentration and related biochemical parameters were measured. We used immunoradiometric assay to determine the levels of IGF-1, HGH and IGFBP-3 in serum.
| Condition |
|---|
|
Hepatitis Liver Cirrhosis Hepatocellular Carcinoma |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Insulin-Like Growth Factor-1,Insulin-Like Growth Factor Binding Protein-3 and Human Growth Hormone in Serum of Patients With Chronic Liver Disease and Possible Clinical Applications. |
serum
| Enrollment: | 210 |
| Study Start Date: | September 2006 |
| Study Completion Date: | March 2008 |
| Primary Completion Date: | March 2008 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
3:
three arms for study
|
Detailed Description:
healthy controls:one blood sample (7.5 cc) hepatitis: three blood samples, at admission, at 3rd and 7-10th day of admission liver cirrhosis: two blood samples, at 1-2 years interval (7.5 cc/each session) hepatocellular carcinoma: three blood samples, before, 1 day after and at the 7th day of transcatheter arterial chembolizatiom
Eligibility| Ages Eligible for Study: | 30 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Acute hepatitis liver cirrhosis hepatocellular carcinoma
Inclusion Criteria:
- Clinical diagnosis of Hepatocellular carcinoma
- Must be primary Hepatocellular carcinoma and untreament
Exclusion Criteria:
- treatment Hepatocellular carcinoma
Contacts and Locations| Taiwan | |
| Division of Radio immunoassay lab,Department of Nuclear Medical University Hospital,No.100 Tzyou 1st Road | |
| Kaohsiung, Taiwan | |
| Principal Investigator: | chiou m Lin, Ms | Kaohsiung Medical University |
More Information
No publications provided
| Responsible Party: | Kaoshing Medical University Chung-Ho Memorial Hospital |
| ClinicalTrials.gov Identifier: | NCT00679692 History of Changes |
| Other Study ID Numbers: | KMUH-IRB-950123, KMUH-IRB-950123 |
| Study First Received: | May 15, 2008 |
| Last Updated: | May 16, 2008 |
| Health Authority: | Taiwan: Institutional Review Board |
Keywords provided by Kaohsiung Medical University Chung-Ho Memorial Hospital:
|
GH,IGF-1, IGFBP-3 |
Additional relevant MeSH terms:
|
Carcinoma Hepatitis Hepatitis A Liver Cirrhosis Fibrosis Liver Diseases Carcinoma, Hepatocellular Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Digestive System Diseases Hepatitis, Viral, Human Virus Diseases |
Enterovirus Infections Picornaviridae Infections RNA Virus Infections Pathologic Processes Adenocarcinoma Liver Neoplasms Digestive System Neoplasms Neoplasms by Site Mitogens Mitosis Modulators Molecular Mechanisms of Pharmacological Action Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 16, 2013